Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to in...
Guardado en:
| Formato: | Online |
|---|---|
| Lenguaje: | inglés |
| Publicado: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Materias: | |
| Acceso en línea: | ONIX_20230220_9783036551623_83 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1869519332023730176 |
|---|---|
| collection | Directory of Open Access Books |
| description | Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system. |
| format | Online |
| id | doab-20.500.12854ir-97480 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-974802024-03-31T13:10:23Z Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Vermehren, Charlotte Westergaard, Niels acute kidney injury early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system. 2023-02-20T16:46:28Z 2023-02-20T16:46:28Z 2022 book ONIX_20230220_9783036551623_83 9783036551623 9783036551616 https://directory.doabooks.org/handle/20.500.12854/97480 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/6018 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-5161-6 10.3390/books978-3-0365-5161-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036551623 9783036551616 224 Basel open access |
| spellingShingle | acute kidney injury early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_full | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_fullStr | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_full_unstemmed | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_short | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_sort | clinical utility of applying pgx and deprescribing based decision support in polypharmacy |
| topic | acute kidney injury early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| topic_facet | acute kidney injury early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| url | ONIX_20230220_9783036551623_83 |